drugset / Trial / NCT06229210
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
Timeline
- Start
- 2024-01-25
- Primary completion
- 2032-04-28
- Completion
- 2032-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lumateperone | Small molecule | 5 mg | Oral |
| Subject | Lumateperone | Small molecule | 42 mg | Oral |